Dataset Information

Current Treatment of Bacterial Vaginosis-Limitations and Need for Innovation.

ABSTRACT: Practitioners and patients alike widely recognize the limitations of current therapeutic approaches to the treatment of bacterial vaginosis (BV). Options remain extremely limited, and our inability to prevent the frequently, often relentless symptomatic recurrences of BV and to reduce serious sequelae such as preterm delivery, remains an acknowledged but unresolved shortcoming. Our incomplete understanding of the pathophysiology of this unique form of vaginal dysbiosis has been a significant impediment to developing optimal treatment and prevention approaches. New drugs have not been forthcoming and are not likely to be available in the immediate future; hence, reliance on the optimal use of available agents has become essential as improvised often unproven regimens are implemented. In this review, we will explore the limitations of currently recommended therapies, with a particular focus on the contribution of reinfection and pathogen persistence to BV recurrence, and the development of interventions that target these mechanisms. Ultimately, to achieve sustained cure and effectiveness against BV-associated sequelae, it is possible that we will need approaches that combine antimicrobials with biofilm-disrupting agents and partner treatments in those at risk of reinfection.

SUBMITTER: Bradshaw CS

PROVIDER: S-EPMC4957510 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Current Treatment of Bacterial Vaginosis-Limitations and Need for Innovation.

Bradshaw Catriona S CS Sobel Jack D JD

The Journal of infectious diseases 20160801

Practitioners and patients alike widely recognize the limitations of current therapeutic approaches to the treatment of bacterial vaginosis (BV). Options remain extremely limited, and our inability to prevent the frequently, often relentless symptomatic recurrences of BV and to reduce serious sequelae such as preterm delivery, remains an acknowledged but unresolved shortcoming. Our incomplete understanding of the pathophysiology of this unique form of vaginal dysbiosis has been a significant imp ...[more]

PMID: 27449869

Similar Datasets

Project description:BACKGROUND:Bacterial vaginosis (BV) is one of the common vaginal infections among childbearing women. The usual treatment for BV is metronidazole; hence 30% of women have recurrence within 60 to 90?days after treatment. There are some studies which assessed the effect of secnidazole on BV. The aim of this systematic review was to investigate the effectiveness of secnidazole for treatment of BV. METHODS:The Cochrane Library, MEDLINE (PubMed), Scopus, and Web of Science (all databases from inception till October 28, 2018) were searched. Primary outcomes were clinical cure rate and microbiologic cure rate and the secondary outcomes were adverse events. Data was extracted from eligible studies by two review authors individually and analyzed by RevMan 5.3. RESULTS:Our search found six trials involving 1528 participants. Treatment with 2?g secnidazole could significantly reduce the risk of BV in patients with three or less episodes of BV in the last year by OR: 7.54 (95% CI, 3.89-14.60, p?<?0.00001) and in patients with four or more episodes of BV in the last year (OR: 4.74, 95% CI: 1.51-14.84, p?=?0.0.008). Secnidazole (2?g) could significantly increase the microbiologic cure rate in women with 3 or less episodes of BV in the last year (OR: 7.63, 95% CI: 2.30-25.33, p?=?0.0009) but not in the women with 4 or more episodes of BV in the last year (OR: 20.17, 95% CI: 1.06-382.45, p?=?0.05). The clinical cure rate, microbiological effect and the therapeutic cure rate of 2?g secnidazole was significantly more than that of 1?g secnidazole. The results showed that the clinical cure rate of 2?g secnidazole was not different from the following medications: metronidazole (500?mg bid for 5?days), secnidazole plus vaginal metronidazole, 2?g single dose of oral metronidazole and 2?g secnidazole plus vaginal ornidazole. CONCLUSION:This review showed that 2?g and 1?g secnidazole were better than placebo, however, 2?g secnidazole was more effective than 1?g. Secnidazole 2?g was not different from metronidazole (500?mg bid for 5?days), or from secnidazole plus vaginal metronidazole, or 2?g single dose of oral metronidazole or from 2?g secnidazole plus vaginal ornidazole.

Dataset Information

Current Treatment of Bacterial Vaginosis-Limitations and Need for Innovation.

Publications

Current Treatment of Bacterial Vaginosis-Limitations and Need for Innovation.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets